🎉 Pharmidex at Olink’s Lunchtime Networking Event! 🎉
February 4, 2025

We are delighted to announce that Martin Barrett, Head of Business Development at Pharmidex, will be attending the Lunchtime Networking Event – Olink PEA Technology Transforming Healthcare:

"The Impact of Proteogenomics" today, February 4, 2025, at Bee House, Milton, Abingdon, UK.


This event is a fantastic opportunity to explore how proteogenomics is shaping the future of healthcare and drug discovery. 

Martin looks forward to meeting fellow professionals, exchanging insights, and expanding Pharmidex’s network to support innovation in drug development.


📍 Event Details:

🗓 Date: February 4, 2025

📌 Location: Bee House, 140 Eastern Ave, Park Dr, Milton, Abingdon OX14 4SB


If you're attending, don’t hesitate to connect with Martin and discover how Pharmidex can help accelerate your drug discovery and development success!

#Pharmidex #Networking #Olink #Proteogenomics #DrugDiscovery #Innovation #Collaboration

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts